Phase 2 N=19 Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Carcinoid Tumor
Primary: Progression Free Survival — 11.8 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Carcinoid Tumors · Pancreatic NET
Primary: Overall Radiographic Response Rate (ORR) — 0 Participants
Phase 2 N=19 Cabozantinib and Nivolumab for Carcinoid Tumors
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Phase 3 N=20 Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).
Photosensitive Epilepsy
Primary: % Change in Frequency of Handwaving Episodes — -66.2 % change in hand waving episodes — p=<0.001
Phase 2 N=15 Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
Carcinoid Syndrome
Primary: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Core Phase — 15; 5 Participants
Phase 2 N=23 Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Carcinoid Syndrome
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase — 4; 3; 3; 2 Participants
Phase 3 N=115 An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Carcinoid Syndrome
Primary: Percentage of Days With Subcutaneous Octreotide as Rescue Medication — 33.72; 48.49 Percentage of days — p=0.0165
Phase 2 N=36 Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Carcinoid Syndrome · Carcinoid · Carcinoid Tumor
Primary: Safety - Incidence of Treatment-emergent Adverse Events (TEAEs) — 16; 15; 10; 9 participants
Phase 3 N=31 Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
Nephrotic Syndrome
Primary: Number of Participants Experienced a Relapse of Nephrotic Syndrome — 14; 15 Participants
Phase 2 N=252 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Adult Hepatocellular Carcinoma · Advanced Adult Hepatocellular Carcinoma · Endometrial Serous Adenocarcinoma
Primary: Progression Free Survival Rate — 0.52; 0.40; 0.71; 0.84 proportion of patients
Phase 2 N=61 Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Carcinoid Tumor · Pancreatic Neuroendocrine Tumor
Primary: Objective Response Rate (ORR) — 3; 7 Participants
Phase 3 N=429 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Carcinoid Tumor · Malignant Carcinoid Syndrome
Primary: Progression Free Survival (PFS) as Per Adjudicated Central Radiology Review — 16.43; 11.33 Months
Phase 2 N=43 A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Carcinoid Tumors
Primary: Progression-Free Survival (PFS) — 14.2 months
Phase 2 N=45 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Carcinoid Tumors
Primary: Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary — 3; 9; 32 participants
Phase 3 N=231 A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Carcinoid Tumor of the Small Bowel · Neuroendocrine Tumour
Primary: Progression Free Survival (PFS) — NA; 8.5 months — p=<0.0001